Could a common heart drug protect newborn brains?
NCT ID NCT06810284
First seen Feb 20, 2026 · Last updated Jun 23, 2026 · Updated 20 times
Summary
This study tests whether adding the drug sildenafil (Revatio) to standard cooling therapy can help prevent brain damage in full-term newborns who suffered oxygen deprivation at birth. The trial will enroll 24 babies and focus on how the drug moves through their bodies. It is a first step toward a larger study that could show if this combination improves survival without brain injury.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPOXIC-ISCHEMIC ENCEPHALOPATHY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Unité de Recherche Clinique, Entrepôts de données et Pharmacologie GHU Paris Centre
Paris, 75005, France
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
sildenafil (Revatio) given intravenously
What this could lead to
If successful, this could pave the way for a larger trial testing whether adding sildenafil to standard cooling therapy improves survival without brain injury in oxygen-deprived newborns.
What could go wrong
This is a small, early-phase study focused on drug levels, not on proving the treatment works. The drug may not show benefit or could cause side effects in fragile newborns.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.